Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 3/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | OGG1 | O15527 | 1/20 | 0.33 |
| ▸ | PSD | A5PKW4 | 2/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.32 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.32 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1869939 | 0.92 | RAB9A (0.36) | MEN1KMT2ARAB9ANPC1TP53 | |
| SCHEMBL1873945 | 0.92 | KMT2A (0.34) | MEN1KMT2ARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL3575367 | 0.90 | NPC1 (0.39) | PTGS1PTGS2RAB9ANPC1TP53 | |
| SCHEMBL2347918 | 0.89 | MAOB (0.40) | MEN1KMT2APTGS1PTGS2RAB9A | |
| SCHEMBL29356089 | 0.89 | MAOB (0.40) | MEN1KMT2APTGS1PTGS2RAB9A | |
| SCHEMBL3622023 | 0.88 | KDR (0.35) | RIPK2EGFRSRCBRAFKDR | |
| SCHEMBL2355084 | 0.87 | CASP1 (0.39) | SMN1; SMN2HSD17B10GABRA1GABRG2GABRB3 | |
| SCHEMBL2347440 | 0.87 | NPC1 (0.39) | MEN1KMT2APTGS2RAB9ANPC1 | |
| SCHEMBL2351307 | 0.87 | IKBKB (0.38) | — | |
| SCHEMBL14199319 | 0.86 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150224105-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE TAUOPATHIES | NIH - DEITR | 2015-08-13 | — | — | US | disclosed |
| US-20150224105-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE TAUOPATHIES | NIH - DEITR | 2015-08-13 | — | — | US | disclosed |
| US-8008512-B2 | Pyridazine compound and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-08-30 | — | — | US | disclosed |
| US-8008512-B2 | Pyridazine compound and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-08-30 | — | — | US | disclosed |
| US-8008512-B2 | Pyridazine compound and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-08-30 | — | — | US | disclosed |
| US-20090281337-A1 | Pyridazine compound and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED | 2009-11-12 | — | — | US | disclosed |
| US-20090281337-A1 | Pyridazine compound and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED | 2009-11-12 | — | — | US | disclosed |
| US-20090281337-A1 | Pyridazine compound and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED | 2009-11-12 | — | — | US | disclosed |
| US-7569518-B2 | Pyridazine Compound and Use Thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-08-04 | — | — | US | disclosed |
| US-7569518-B2 | Pyridazine Compound and Use Thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-08-04 | — | — | US | disclosed |
| US-7569518-B2 | Pyridazine Compound and Use Thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-08-04 | — | — | US | disclosed |
| EP-1767529-B1 | PYRIDAZINE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL CO (JP) | 2009-05-06 | — | — | EP | disclosed |
| US-20080194566-A1 | Pyridazine Compound and Use Thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2008-08-14 | — | — | US | disclosed |
| US-20080194566-A1 | Pyridazine Compound and Use Thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2008-08-14 | — | — | US | disclosed |
| US-20080194566-A1 | Pyridazine Compound and Use Thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2008-08-14 | — | — | US | disclosed |
| EP-1767529-A1 | PYRIDAZINE COMPOUND AND USE THEREOF | Sumitomo Chemical Company, Limited (JP) | 2007-03-28 | — | — | EP | disclosed |
| EP-1767529-A1 | PYRIDAZINE COMPOUND AND USE THEREOF | Sumitomo Chemical Company, Limited (JP) | 2007-03-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194566-A1 | Pyridazine Compound and Use Thereof | PLPBP, PNPO, CYP4Z1 | MEN1 2346/4885KMT2A 2463/4885AR 4822/4885 |
| US-20150224105-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE TAUOPATHIES | MAPT, SYNJ1, PARK7 | MEN1 4395/4885KMT2A 2523/4885AR 4601/4885 |
| US-20090281337-A1 | Pyridazine compound and use thereof | PLPBP, PNPO, CYP4Z1 | MEN1 2346/4885KMT2A 2463/4885AR 4822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.